Prevention of excessive endothelin-1 release in sclerotherapy: in vitro and in vivo studies

Related Experiment Video

Updated: Apr 20, 2026

Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium
05:53

Intraluminal Drug Delivery to the Mouse Arteriovenous Fistula Endothelium

Published on: March 4, 2016

9.9K

David M Duffy1

  • 1Department of Dermatology, University of Southern California, Los Angeles Torrance, California.

Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [Et Al.]
|November 25, 2014
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Procedure for Human Saphenous Veins Ex Vivo Perfusion and External Reinforcement09:50

Procedure for Human Saphenous Veins Ex Vivo Perfusion and External Reinforcement

Published on: October 1, 2014

11.9K
Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices02:14

Underwater Endoscopic Injection Sclerotherapy for Gastroesophageal Varices

Published on: August 1, 2025

2.2K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
588